Finasteride can help, but it takes about 6 months to reduce the prostate volume in "normal" people (I mean not taking aas; I have no studies about aas and finasteride on prostate disease).
Prostate cancer is much more dangerous than the benign prostate growth.
It give no symptoms until it is pretty advanced.
Some people use to check thei PSA every year or so to detect an early prostate cancer.
Still, once you have cancer, you can only treat it and hope.
Androgens speed up the growth of prostate cancer.
It is not clear whether androgens can actually start the cancer or only help it to grow faster and stronger one sth else has started the shit.
Still, once you have prostate cancer you are done with aas and alike.
There are a few interesting research going on in the world (yes, there is a world out there), about the possible preventive effect of finasteride towards prostate cancer.
Results are expected in 2004.
I am waiting.
More on this later, IF SBD IS INTERESTED.
I have got to go now!
Eagle
Eur J Cancer Prev 2002 Aug;11 Suppl 2:S18-27
Chemoprevention strategies for prostate cancer.
Bosland MC, McCormick DL, Melamed J, Walden PD, Zeleniuch-Jacquotte A, Lumey LH.
Department of Environmental Medicine, New York University School of Medicine, 550 First Avenue, New York, NY 10016, USA.
[email protected]
Prostate cancer is the most common male malignancy in western countries.
Although primary prevention of prostate cancer is not possible, screening using prostate-specific antigen (PSA) may eliminate prostate cancers by definitive treatments.
Prevention of clinically detectable prostate cancer requires earlier chemoprevention interventions.
Because
prostate cancer is histologically present in 30-50% of 30- to 50-year-old men, effective chemoprevention needs to inhibit not only prostate carcinogenesis but also growth and progression of these cancers.
AND ANDROGENS SPEED UP THE CANCER GROWTH.....
A prostate carcinogenesis animal model has been used to screen
chemopreventive agents; inhibitory effects were found with 9-cis-retinoic acid, dehydroepiandrosterone, fluasterone, and the Bowman-Birk inhibitor and an isoflavone mixture which both occur in soy.
Such results can be used to select agents for clinical trials.
Besides large-scale long-duration prevention trials, trials of short/intermediate duration using smaller cohorts prior to or following radical prostatectomy may provide excellent and cost-effective approaches for chemopreventive agent efficacy testing.
Intervention prior to surgery allows measurements of intervention agents and intermediate end-points in the prostate.
These peri-surgical trials only assess inhibition of growth and progression of preexisting cancer, not real preventive effects, but they focus on clinically significant cancers. Such trials are an essential step in the development of antiprostate cancer chemoprevention agents.